<rss version="2.0">
<channel>
<title>Cancer Trials Advocacy Group News RSS Feed</title>
<link>http://www.cancertrials4prostate.org</link>
<description>Clinical Trials Advocacy Group for Prostate Cancer provides a comprehensive listing of all Phase 2, Phase 3, and Phase 4 clinical trials for the treatment of prostate cancer that are currently recruiting patients in the U.S. and Canada</description>  
<item><title><![CDATA[Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial]]></title>
									<link>http://cancertrials4prostate.com/news?id=173</link>
									<description><![CDATA[Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon™ DNA vaccine for prostate cancer targeting two antigens.]]></description>
									<pubDate>Fri, 11 Feb 2011 00:00:00 MDT</pubDate></item><item><title><![CDATA[Isis Initiates Broad Phase 2 Program of ISIS-EIF4ERx in Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=172</link>
									<description><![CDATA[Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer.  These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer.  ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.]]></description>
									<pubDate>Tue, 04 Jan 2011 00:00:00 MDT</pubDate></item><item><title><![CDATA[Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy]]></title>
									<link>http://cancertrials4prostate.com/news?id=174</link>
									<description><![CDATA[Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy]]></description>
									<pubDate>Tue, 04 Jan 2011 00:00:00 MDT</pubDate></item><item><title><![CDATA[Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=170</link>
									<description><![CDATA[Centocor Ortho Biotech Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic advanced prostate cancer in patients who have received prior chemotherapy containing a taxane.]]></description>
									<pubDate>Mon, 20 Dec 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Beaumont Hospital Launches Study of Single-Dose Radiation Treatment for Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=171</link>
									<description><![CDATA[Beaumont Hospital radiation oncologists have launched a research study to treat men with low to intermediate risk prostate cancer with a single dose of radiation]]></description>
									<pubDate>Thu, 16 Dec 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Avodart Reviewed by FDA Advisory Committee for Prostate Cancer Risk Reduction]]></title>
									<link>http://cancertrials4prostate.com/news?id=168</link>
									<description><![CDATA[GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA). When asked if the dutasteride risk/benefit profile is favorable for reduction in the risk of prostate cancer in this target population, the ODAC voted 14 against, 2 in favor, and 2 abstentions.]]></description>
									<pubDate>Thu, 02 Dec 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[A Degarelix Trial in Patients With Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=169</link>
									<description><![CDATA[An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy]]></description>
									<pubDate>Thu, 02 Dec 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Medivation and Astellas Complete Enrollment in Phase 3 Affirm Trial of MDV3100 in Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=167</link>
									<description><![CDATA[Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy.]]></description>
									<pubDate>Mon, 29 Nov 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=166</link>
									<description><![CDATA[Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bicalutamide together with RO4929097 may be an effective treatment for prostate cancer.]]></description>
									<pubDate>Tue, 02 Nov 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=165</link>
									<description><![CDATA[This phase II trial is studying how well giving atorvastatin calcium together with celecoxib works in treating patients with rising PSA levels after local therapy for prostate cancer.]]></description>
									<pubDate>Wed, 13 Oct 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer (PROACT)]]></title>
									<link>http://cancertrials4prostate.com/news?id=117</link>
									<description><![CDATA[A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer]]></description>
									<pubDate>Mon, 11 Oct 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)]]></title>
									<link>http://cancertrials4prostate.com/news?id=118</link>
									<description><![CDATA[The purpose of this study is to determine the benefit of MDV3100 versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.]]></description>
									<pubDate>Mon, 11 Oct 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Prospective Study of Metformin in Castration-Resistant Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=116</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 05 Oct 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet]]></title>
									<link>http://cancertrials4prostate.com/news?id=115</link>
									<description><![CDATA[BRIDGEWATER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE:  SNY) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana® (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet  in an article titled "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial." ]]></description>
									<pubDate>Fri, 01 Oct 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER]]></title>
									<link>http://cancertrials4prostate.com/news?id=114</link>
									<description><![CDATA[The SYNERGY trial is a randomized, controlled, global Phase 3 trial to be conducted in approximately 125 cancer centers and with designated recruitment of 800 men with metastatic CRPC who have disease progression and require first-line docetaxel/prednisone chemotherapy.]]></description>
									<pubDate>Thu, 30 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=113</link>
									<description><![CDATA[NEW YORK, Sept. 27  /PRNewswire-FirstCall/ -- Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer (CRPC) that had progressed despite treatment with a docetaxel-based chemotherapy regimen.  During a scheduled interim analysis, an independent Data Monitoring Committee (DMC) found that the combination of sunitinib with prednisone was unlikely to improve overall survival when compared to prednisone alone.]]></description>
									<pubDate>Tue, 28 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=111</link>
									<description><![CDATA[BOTHELL, WA and VANCOUVER, Sept. 27 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ:  OGXI) announced today the initiation of a randomized, controlled, investigator-sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.]]></description>
									<pubDate>Mon, 27 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)]]></title>
									<link>http://cancertrials4prostate.com/news?id=112</link>
									<description><![CDATA[SINGAPORE, Sept. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC). ]]></description>
									<pubDate>Mon, 27 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial]]></title>
									<link>http://cancertrials4prostate.com/news?id=110</link>
									<description><![CDATA[BOTHELL, WA and VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ:  OGXI) announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer.]]></description>
									<pubDate>Wed, 22 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Hybrigenics Unveils Positive Final Results Of Inecalcitol Phase IIa Clinical Study In Hormone-Refractory Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=109</link>
									<description><![CDATA[Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments, today announces the positive outcomes of clinical tolerance Phase IIa study of daily oral inecalcitol in combination with gold standard Taxotere(R) chemotherapy in hormone-refractory prostate cancer patients]]></description>
									<pubDate>Tue, 21 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Harbor reports positive data from Phase II/III prostate cancer trial]]></title>
									<link>http://cancertrials4prostate.com/news?id=108</link>
									<description><![CDATA[Harbor BioSciences, a biopharmaceutical company, has announced new positive data from its ongoing Phase I/IIa clinical trial with Apoptone for castration resistant prostate cancer, or CRPC, also referred to as hormone resistant prostate cancer.]]></description>
									<pubDate>Thu, 16 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Abiraterone after Ketoconazole]]></title>
									<link>http://cancertrials4prostate.com/news?id=105</link>
									<description><![CDATA[In September 2010, the University of California (San Francisco) initiated a Phase 2 clinical trial of abiraterone for men with castrate resistant prostate cancer that have progressed after being treated with ketoconazole]]></description>
									<pubDate>Sat, 11 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=103</link>
									<description><![CDATA[This is a Phase 1 clinical trial of neoadjuvant (pre-prostatetcomy) gene therapy followed by prostatectomy for men with a high risk of cancer recurrence after radical prostatectomy]]></description>
									<pubDate>Fri, 10 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria]]></title>
									<link>http://cancertrials4prostate.com/news?id=104</link>
									<description><![CDATA[LOS ANGELES, Sept. 9  /PRNewswire/ -- Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.  ]]></description>
									<pubDate>Fri, 10 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Study of MLN8237 in Patients With Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen]]></title>
									<link>http://cancertrials4prostate.com/news?id=102</link>
									<description><![CDATA[This is a Phase 2 clinical trial of MLN8237, an experimental drug,  used in combination with docetaxel as a treatment for metastatic, castration-resistant prostate cancer (CRPC)]]></description>
									<pubDate>Thu, 09 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[EDAP Reports Publication of Long-Term Clinical Results for Largest Cohort of Ablatherm-HIFU Patients]]></title>
									<link>http://cancertrials4prostate.com/news?id=101</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 08 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in the Treatment of Patients With Castration-Resistant Prostate Cancer Resistant to Docetaxel]]></title>
									<link>http://cancertrials4prostate.com/news?id=99</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 07 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[CytRx Initiates Phase 2 Clinical Trial with Bafetinib in Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=100</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 07 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[TroVax In Subjects With Hormone Refractory Prostate Cancer (HRPC)]]></title>
									<link>http://cancertrials4prostate.com/news?id=98</link>
									<description><![CDATA[]]></description>
									<pubDate>Mon, 06 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Speakers to discuss prostate cancer (at the Barbara Ann Karmanos Cancer Center in Farmington Hills, Michigan)]]></title>
									<link>http://cancertrials4prostate.com/news?id=97</link>
									<description><![CDATA[]]></description>
									<pubDate>Sun, 05 Sep 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[The Importance of Clinical Trials ]]></title>
									<link>http://cancertrials4prostate.com/news?id=94</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 31 Aug 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Laser Based Focal Ablation of Low Grade Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=95</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 27 Aug 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=90</link>
									<description><![CDATA[]]></description>
									<pubDate>Thu, 19 Aug 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Aragon Pharmaceuticals doses first patient in Phase 1/2 clinical trial of ARN-509 for castration-resistant prostate cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=83</link>
									<description><![CDATA[]]></description>
									<pubDate>Mon, 09 Aug 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108]]></title>
									<link>http://cancertrials4prostate.com/news?id=86</link>
									<description><![CDATA[]]></description>
									<pubDate>Thu, 05 Aug 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[New Clinical Trial Offers Vascular-Targeted Photodynamic Therapy to Patients with Localized Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=92</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 27 Jul 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=88</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 14 Jul 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Leuprolide Acetate or Goserelin With or Without GDC-0449 Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=89</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 14 Jul 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=87</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 30 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[FDA approves (Provenge) vaccine to treat prostate cancer ]]></title>
									<link>http://cancertrials4prostate.com/news?id=93</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 29 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Radium-223 Shows Early Promise In Prostate Cancer Patients With Bone Metastases]]></title>
									<link>http://cancertrials4prostate.com/news?id=78</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 25 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[BioWatch: Northwest's cancer results fuel interest]]></title>
									<link>http://cancertrials4prostate.com/news?id=79</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 25 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=76</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 22 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=85</link>
									<description><![CDATA[]]></description>
									<pubDate>Mon, 21 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[FDA Approves New Treatment for Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=84</link>
									<description><![CDATA[]]></description>
									<pubDate>Thu, 17 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[FDA approves Provenge for the treatment of prostate cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=50</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 16 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[A news video about Provenge]]></title>
									<link>http://cancertrials4prostate.com/news?id=51</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 16 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=52</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 15 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[PET Acetate for Castrate-Resistant Prostate Cancer  on Chemotherapy]]></title>
									<link>http://cancertrials4prostate.com/news?id=54</link>
									<description><![CDATA[]]></description>
									<pubDate>Sun, 13 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)]]></title>
									<link>http://cancertrials4prostate.com/news?id=55</link>
									<description><![CDATA[]]></description>
									<pubDate>Mon, 07 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Denosumab Demonstrated Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=68</link>
									<description><![CDATA[]]></description>
									<pubDate>Sat, 05 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer (CRPC)]]></title>
									<link>http://cancertrials4prostate.com/news?id=69</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 04 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[FIRMAGON® Results in Fast, Long-Term Suppression of Testosterone in Prostate Cancer Patients Without Initial Testosterone Surge]]></title>
									<link>http://cancertrials4prostate.com/news?id=70</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 01 Jun 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting]]></title>
									<link>http://cancertrials4prostate.com/news?id=71</link>
									<description><![CDATA[]]></description>
									<pubDate>Mon, 31 May 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial]]></title>
									<link>http://cancertrials4prostate.com/news?id=72</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 11 May 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=56</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 30 Apr 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)]]></title>
									<link>http://cancertrials4prostate.com/news?id=57</link>
									<description><![CDATA[]]></description>
									<pubDate>Thu, 29 Apr 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=73</link>
									<description><![CDATA[]]></description>
									<pubDate>Thu, 29 Apr 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Study of MLN8237 in Patients With Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen]]></title>
									<link>http://cancertrials4prostate.com/news?id=77</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 17 Mar 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Temsirolimus (Torisel) and Bevacizumab (Avastin) in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy]]></title>
									<link>http://cancertrials4prostate.com/news?id=58</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 05 Mar 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery]]></title>
									<link>http://cancertrials4prostate.com/news?id=59</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 02 Mar 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[A Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men With Castrate Resistant Prostate Cancer (CRPC)]]></title>
									<link>http://cancertrials4prostate.com/news?id=60</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 26 Feb 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=61</link>
									<description><![CDATA[]]></description>
									<pubDate>Wed, 24 Feb 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy]]></title>
									<link>http://cancertrials4prostate.com/news?id=62</link>
									<description><![CDATA[]]></description>
									<pubDate>Mon, 22 Feb 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=63</link>
									<description><![CDATA[]]></description>
									<pubDate>Tue, 26 Jan 2010 00:00:00 MDT</pubDate></item><item><title><![CDATA[Cixutumumab and Temsirolimus (Torisel) in Treating Patients With Metastatic Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=64</link>
									<description><![CDATA[]]></description>
									<pubDate>Thu, 03 Dec 2009 00:00:00 MDT</pubDate></item><item><title><![CDATA[Temsirolimus (TORISEL) to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer]]></title>
									<link>http://cancertrials4prostate.com/news?id=66</link>
									<description><![CDATA[]]></description>
									<pubDate>Fri, 30 Oct 2009 00:00:00 MDT</pubDate></item><item><title><![CDATA[Study to Evaluate Safety and Effectiveness of Lenalidomide (REVLIMID) in Combination With Docetaxel (Taxotere) and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)]]></title>
									<link>http://cancertrials4prostate.com/news?id=67</link>
									<description><![CDATA[]]></description>
									<pubDate>Thu, 01 Oct 2009 00:00:00 MDT</pubDate></item>    
    
  </channel>
</rss> 